Ayala Pharmaceuticals Inc. (ADXS)

Ayala Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.01	0.01	0.25	3.24	0.25	2.33
Revenue Growth (YoY)	-97.98%	-94.80%	-92.28%	1180.63%	-89.16%	-61.50%
Cost of Revenue	7.14	0.01	0.31	3.71	1.29	1.29
Gross Profit	-7.13	0	-0.06	-0.47	-1.03	1.05
Selling, General & Admin	12.19	12.19	8.42	11.46	11.09	4.34
Research & Development	24.08	24.08	7.61	10.56	15.61	14.42
Other Operating Expenses	0	0	3.05	-0	-0	0
Operating Expenses	36.27	36.27	16.03	22.03	26.7	18.76
Operating Income	-36.27	-36.27	-16.09	-18.79	-26.45	-17.71
Interest Income	0.3	0.03	0.07	0.01	0.11	0.23
Interest Expense	-0.22	15.75	0	0.26	0	0
Other Expense / Income	16.23	-	-1.71	-1.23	0.08	-
Pretax Income	-51.98	-51.98	-14.31	-17.81	-26.42	-17.49
Income Tax	-3.91	-3.91	0.05	0.05	0.05	0.31
Net Income	-48.07	-48.07	-14.36	-17.86	-26.47	-17.79
Shares Outstanding (Basic)	6	6	2	2	1	0
Shares Outstanding (Diluted)	6	6	2	2	1	0
Shares Change	230.97%	230.97%	12.70%	111.61%	301.14%	-94.47%
EPS (Basic)	-9.12	-7.99	-7.90	-11.07	-34.71	-93.60
EPS (Diluted)	-9.12	-7.99	-7.90	-11.07	-34.71	-93.60
Free Cash Flow	-20.92	-29.49	-15.49	-15.9	-22.69	-16.28
Free Cash Flow Per Share	-3.48	-4.90	-8.51	-9.85	-29.75	-85.64
Gross Margin	-54853.85%	-	-25.60%	-14.44%	-407.91%	44.94%
Operating Margin	-278969.23%	-278969.23%	-6436.00%	-579.81%	-10454.15%	-758.83%
Profit Margin	-369784.62%	-369784.62%	-5743.60%	-551.30%	-10462.06%	-762.30%
Free Cash Flow Margin	-160953.85%	-226807.69%	-6194.00%	-490.71%	-8967.59%	-697.51%
EBITDA	-35.92	-35.87	-15.78	-18.77	-24.39	-17.56
EBITDA Margin	-276338.46%	-275915.38%	-6310.40%	-579.20%	-9641.90%	-752.40%
Depreciation & Amortization	0.31	0.37	0.31	0.99	1.98	0.15
EBIT	-36.24	-36.24	-16.09	-19.76	-26.37	-17.71
EBIT Margin	-278753.85%	-278753.85%	-6436.00%	-609.75%	-10423.72%	-758.83%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.